SGLT2 Inhibitors versus Sulfonylureas as Add-On Therapy to Metformin in Type 2 Diabetes: A Systematic Review and Meta-Analysis

被引：0
|
作者：
Umer, Muhammed
Salman, Ali
Nadeem, Shahrukh
Iqbal, Abiha
Tashrifwala, Fatema
Paryani, Neha Saleem
Ali, Eman
Kumar, Jai
Maniya, Muhammad Talha
Asad, Dayab
机构：
来源：
CIRCULATION | 2023年 / 148卷
关键词：
Diabetes (Type II);
D O I：
10.1161/circ.148.suppl_1.14623
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A14623
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Combination Therapy with an SGLT2 Inhibitor as Initial Treatment for Type 2 Diabetes: A Systematic Review and Meta-Analysis
    Milder, Tamara Y.
    Stocker, Sophie L.
    Shaheed, Christina Abdel
    McGrath-Cadell, Lucy
    Samocha-Bonet, Dorit
    Greenfield, Jerry R.
    Day, Richard O.
    JOURNAL OF CLINICAL MEDICINE, 2019, 8 (01)
  • [22] Durability of glycemic control with rosiglitazone versus sulfonylureas as add-on therapy to metformin for patients with type 2 diabetes
    Thompson, D
    Bogard, E
    McGarry, L
    Taylor, D
    Safriet, S
    Dirani, R
    O'Neill, MC
    DIABETES, 2004, 53 : A148 - A148
  • [23] Cardiovascular safety and efficacy of metformin-SGLT2i versus metformin-sulfonylureas in type 2 diabetes: systematic review and meta-analysis of randomized controlled trials
    Gebrie, Desye
    Getnet, Desalegn
    Manyazewal, Tsegahun
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [24] Cardiovascular safety and efficacy of metformin-SGLT2i versus metformin-sulfonylureas in type 2 diabetes: systematic review and meta-analysis of randomized controlled trials
    Desye Gebrie
    Desalegn Getnet
    Tsegahun Manyazewal
    Scientific Reports, 11
  • [25] SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: A systematic review and meta-analysis
    Seidu, Samuel
    Kunutsor, Setor K.
    Cos, Xavier
    Gillani, Syed
    Khunti, Kamlesh
    PRIMARY CARE DIABETES, 2018, 12 (03) : 265 - 283
  • [26] SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials
    Tang, Huilin
    Dai, Qi
    Shi, Weilong
    Zhai, Suodi
    Song, Yiqing
    Han, Jiali
    DIABETOLOGIA, 2017, 60 (10) : 1862 - 1872
  • [27] Effects of SGLT2 inhibitors on stroke and its subtypes in patients with type 2 diabetes: a systematic review and meta-analysis
    Tsai, Wen-Hsuan
    Chuang, Shih-Ming
    Liu, Sung-Chen
    Lee, Chun-Chuan
    Chien, Ming-Nan
    Leung, Ching-Hsiang
    Liu, Shu-Jung
    Shih, Hong-Mou
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [28] Dose-ranging effects of SGLT2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis
    Pinto, Lana C.
    Rados, Dimitris, V
    Remonti, Luciana R.
    Viana, Marina V.
    Leitao, Cristiane B.
    Gross, Jorge L.
    ARCHIVES OF ENDOCRINOLOGY METABOLISM, 2022, 66 (01): : 68 - 76
  • [29] Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis
    Jiali Liu
    Ling Li
    Sheyu Li
    Pengli Jia
    Ke Deng
    Wenwen Chen
    Xin Sun
    Scientific Reports, 7
  • [30] Dose-ranging effects of SGLT2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis
    Pinto, L. C.
    Rados, D. R.
    Retnonti, L. R.
    Viana, M. V.
    Leitao, C. B.
    Gross, J. L.
    DIABETOLOGIA, 2018, 61 : S313 - S313
12345